Home > Oncology > Changes in genitourinary cancer management during the pandemic: findings and implications

Changes in genitourinary cancer management during the pandemic: findings and implications

Expert
Dr Chris Labaki, Dana-Farber Cancer Institute, MA, USA

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
ASCO GU 2022
A significant drop in the screening, diagnosis, and treatment of genitourinary cancers was observed during the early months of the COVID-19 pandemic, followed by a progressive recovery. Notably, the screening rate for prostate-specific antigen was reduced the most, whereas declines in cystectomies were relatively limited. This pattern reflects the triaging of care based on severity that was exercised during the COVID-19 pandemic [1]. Medicom interviewed Dr Chris Labaki (Dana-Farber Cancer Institute, MA, USA), who presented the findings of a study conducted by the Mass General Brigham System during the annual genitourinary cancer symposium of the American Society of Clinical Oncology’s Genitourinary Cancers Symposium (GU22), h...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on